Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Plus Gliclazide vs Metformin in T2DM
NCT06613750Phase 4Completed
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sitagliptin and gliclazide in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change in Glycated Hemoglobin (HbA1c) Levels at 12 weeks. Started Jun 2024; status: completed.
02
Drugs
sitagliptingliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06613750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613750.